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 Conference Reports
test Guidelines OPPtS 8706300 on DNt (US ePA, 1998) and 
in 2007 the Organization for economic Cooperation and Devel-
opment (OeCD) endorsed a new OeCD DNt test Guideline 
426 (OeCD, 2007). these guidelines are largely based on ani-
mal studies and are used as higher tiered, triggered tests based 
on structure activity relationships or evidence of neurotoxic-
ity in standard adult, developmental, or reproduction studies 
(Makris et al., 2009). 
experts at the conference stated that these in vivo tests are 
unsuitable for screening large numbers of chemicals for many 
reasons including low throughput, high cost, and questions re-
garding reliability. there was also consensus that new, reliable, 
and efficient screening and assessment tools are needed for bet-
ter identification, prioritization, and evaluation of chemicals 
with the potential to induce developmental neurotoxicity. the 
information obtained from these screening studies will likely 
also help to refine animal tests and to inform epidemiological 
studies. 
1  Introduction
the 3rd International Conference on Alternatives for Develop-
mental Neurotoxicity testing (DNt3), organized by the eu-
ropean Centre for the Validation of Alternative Methods (eC-
VAM), Joint Research Centre of the european Commission, 
was held on May 10 - 13, 2011 in Varese, Italy. Over 100 experts 
from 18 different countries attended. DNt3 achieved its pri-
mary goal of bringing together diverse stakeholders including 
research scientists, industry representatives, academia, clinical 
representatives, and experts from regulatory bodies from both 
europe and the US. A majority of new participants were from 
european countries that had not attended the two previous DNt 
conferences held in the United States in 2006 and 2008. Hold-
ing the conference in europe also facilitated new trans-Atlantic 
contacts among researchers interested in DNt. 
 At the regulatory level, there is a recognized need for DNt 
testing. As early as 1998, the ePA published the Health effects 
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the required features of alternative test methods that would 
be capable of screening large numbers of chemicals for their 
DNT profile were discussed in detail. It was proposed that new 
data must be produced using batteries of in vitro tests that in-
corporate different DNt-relevant endpoints in high-throughput 
systems and test a wide range of concentrations of test chemi-
cals. Higher throughput screening methods should be validated 
if they are used for regulatory purposes. 
 the applied models must be based on evolutionarily con-
served neurodevelopmental processes that are mechanistically 
relevant for human developmental neurotoxicity. In the next 
step, these test methods should be validated with the goal of 
obtaining regulatory acceptance. Moreover, cell-cell and organ-
organ interactions must be taken into account for valid DNt 
screening systems, though this requirement presents major tech-
nical challenges to non-animal test systems, but is a strength of 
the non-mammalian alternative animal models. 
 there was general agreement that methods for a high-through-
put screening battery should be developed using recommenda-
tions proposed by Crofton et al. (2011), see Box 1. the expecta-
tion is that test methods developed with these recommendations 
would generate reliable data that could be evaluated across test 
methods and across laboratories and would allow comparison 
of their predictive capacity and efficiency. This comparative ap-
proach would be useful for demonstrating that a given test meth-
od performs adequately for the intended purpose (validation) 
and could hence be accepted for regulatory applications. 
Maximizing the opportunities for reducing, refining or re-
placing animal experiments should be kept in mind during this 
process. However, participants also agreed that there is still a 
The conferees confirmed that DNT is an issue of growing glo-
bal concern and that damage of the developing brain by chemi-
cal exposure results in significant societal as well as individual 
costs. A particular challenge in DNt is that the neurodevelop-
mental outcome of exposure to potentially neurotoxic chemi-
cals depends not only on the kind of exposure (dose, duration) 
but also on the developmental stage at the time of exposure. 
Participants discussed a variety of alternative methods with this 
challenge in mind. 
 there is increasing pressure from a variety of children’s health 
advocacy groups being placed on industry, academia, and regu-
latory bodies to develop (alternative) methods that reliably and 
efficiently screen large numbers of chemicals for which we cur-
rently have little or no information concerning their potential for 
developmental neurotoxicity. In vitro and non-mammalian alter-
native systems-based models are prime candidates, but also in 
silico methods and combinations should be considered. As a first 
step, methods are needed for identifying the effects of chemicals 
on developmental processes critical to the formation of a func-
tional nervous system. Alternative test methods must then be re-
fined to meet regulatory requirements for identifying potential 
developmental neurotoxicants in a fast, affordable, and reliable 
way, ideally also providing potency information that is needed 
for risk assessment. Most likely this can only be achieved with 
non-animal test methods, but where this cannot (yet) be realized, 
any new approach should respect animal welfare and the 3Rs, 
i.e., it should aim to refine, reduce, and ultimately replace ani-
mal experiments. Even before regulatory acceptance, scientifi-
cally robust methods could be used for prioritizing chemicals for 
further DNt studies under the ePA and OeCD guidelines. 
1) ADVERSITY and SPECIFICITY  
(i.e., to developmental neurotoxicity)·	What	is	the	definition	of	adversity	in	your	assay	or	battery  of assays?·	How	can	a	specific	effect	on	nervous	system	development	be distinguished from overt toxicity (i.e., cytotoxicity for  
in vitro tests, death or malformations for alternative species 
tests)?· How can the relative potency be compared, within and across assays, for a more complete understanding of  
the predictive potential of in vivo (i.e., ultimately human 
health) effects? · What is the complement of data that will be needed  in using “screening and prioritization” assays to support  
concern (in the regulatory sense) regarding potential 
 developmental neurotoxicity for a given chemical? 
2) ASSAY RELIABILITY·	What	type	of	in	silico	conditions	must	be	met	or	defined?· What is the minimal number of replicates?
· How can variability in the data be expressed? · What is the minimum number of doses that should be  included?· What dose spacing is optimal (e.g., log, ½ log, ¼ log, etc.)?·	What	is	the	definition	of	dose?	· How can relative potency be characterized? 
3) ASSAY DESIGN · How should results be expressed so that there can be com-parisons (e.g., NOEC, LD (st.dev), EC50, EC30, etc.)?·	How	do	you	decide	what	is	a	significant	difference	from	control conditions?· What positive and negative controls should be tested for each type of assay?·	What	details	regarding	specific	experimental	conditions	and	
methods	must	be	defined?· What measures of overt toxicity (i.e., cytotoxicity for in vitro tests, death or malformations for the alternative species 
tests) are appropriate?
Box 1: Examples of questions that need to be addressed in order to develop specific criteria that facilitate comparisons of assays 
(Crofton et al. 2011)
ConferenCe reports
Altex 29, 2/12204
and lord, 1943). Similarly, early discoveries of methylmercu-
ry, ethanol, and polychlorinated biphenyls exposures were not 
considered sufficient evidence to trigger regulatory action, thus 
causing delays in preventive actions (Grandjean, 2008a). the 
expenses caused by these delays in prevention are now becom-
ing clear.
 Although the fetus was considered well protected inside the 
mother’s womb, research has shown that the protection may not 
include environmental toxicants. A study of matched mother-
infant samples showed that the placenta offers little protection 
for most chemicals (Needham et al., 2011), and many environ-
mental chemicals are transferred to the infant via human milk. 
In relation to body weight, children’s contaminant exposures 
can be excessive. these concerns relate to a large number of 
substances. thus, a US study of umbilical cord blood samples 
showed the presence of 287 environmental chemicals (environ-
mental Working Group, 2005). the majority of them have not 
been examined in regard to developmental neurotoxicity.
evidence of human neurotoxicity from industrial chemicals 
(other than pharmaceuticals) is based on inadvertent poison-
ings, occupational exposures, suicidal attempts, and similar ob-
servational data, where doses may not be known and control 
groups are absent. Nonetheless, careful scrutiny of existing data 
has shown that at least 200 industrial chemicals are associated 
with neurotoxic changes in humans (Grandjean and landrigan, 
2006). the list of neurotoxicants includes at least 90 pesticides, 
25 metals and inorganic compounds, 43 solvents, and 43 other 
industrial chemicals. these numbers may be a substantial un-
derestimation of the true number of environmental neurotoxi-
cants, but they may reflect a greater neurotoxic risk associated 
with pesticides and solvents.
 With regard to developmental neurotoxicity, all of the 200 
adult human neurotoxicants (mentioned above) may be consid-
ered capable also of causing damage to the developing brain; 
however, developmental neurotoxicity has been documented 
only for an exceedingly small number of these chemicals. 
Again, such research relies on ‘natural experiments’ where 
children have been exposed to a substance pre- and postnatally, 
and where brain development can be examined in relation to 
indicators of exposure levels. As many tests are not feasible be-
fore school age, or have a low predictive validity in regard to 
mature brain function, such studies will often require testing of 
brain functions many years after the prenatal or early postnatal 
exposure to the suspected neurotoxicant. thus, research in this 
field takes a very long time, perhaps a prohibitive duration of 
follow-up, resources, and commitment. In 1990, a workshop 
report listed ethanol, PCBs, lead, phenytoin, ionizing radiation, 
methylmercury, and some drugs of abuse (e.g., cocaine, heroin, 
methadone) as generally recognized human developmental neu-
rotoxicants (Rees et al., 1990). More recently the evidence of 
developmental neurotoxicity of environmental chemicals was 
considered as judged sufficient only for arsenic, lead, methylm-
ercury, polychlorinated biphenyls, and toluene (Grandjean and 
Landrigan, 2006). Among present day candidates are fluoride, 
manganese, polyaromatic hydrocarbons, and organophosphate 
pesticides. this list is likely not to be complete due to the lack 
of systematic testing for developmental neurotoxicity.
long way to go before we have good models for integrating and 
interpreting data from in vitro and other alternatives that would 
be sufficient for assessing human risks. 
The conference concluded with views of regulatory officials 
from the european Commission and the US environmental Pro-
tection Agency (ePA). In their closing remarks, Dr Alan Gold-
berg (Center for Alternatives to Animal testing (CAAt, US) 
and Dr Joachim Kreysa (eCVAM, eU) applauded the progress 
made since DNt2, but concluded that much work is still needed 
to develop scientifically robust tests that will provide all stake-
holders with the data needed for risk assessment and risk man-
agement decisions. Initially identifying those environmental 
chemicals with the greatest potential to disturb the development 
of the human brain and central nervous system should receive 
highest priority. 
Dr Goldberg announced that the 4th conference on DNt 
will be held in the United States and, in recognition of rapid 
progress in the field, will be scheduled within the next two 
years. 
this report summarizes the main topics discussed during the 
meeting and presents conclusions and recommendations made 
for future directions and priorities.
2  Environmental perspectives of  
developmental neurotoxicity
Philippe Grandjean 
Since the term ‘silent pandemic’ was proposed to reflect the 
prevalence of developmental neurotoxicity in children exposed 
to environmental chemicals (Grandjean and landrigan, 2006), 
the problem has been further characterized and additional sub-
stances have been documented as neurotoxicants (Julvez and 
Grandjean, 2009). A major obstacle, however, remains: con-
vincing ‘proof’ is required before initiating protection against 
neurotoxic substances. For several reasons, regulation of devel-
opmental neurotoxicants must recognize the known sensitivity 
of the developing brain. there are many reasons for the use of 
a precautionary approach to protect the brain functions of the 
next generation. 
 First of all, brain development can be highly vulnerable to 
chemical toxicity, as optimal brain development relies on cell 
multiplication, differentiation, migration, and cell-cell interac-
tions occurring in a particular sequence and at the right time. 
Cognition and behavior depend on the functions of the brain as 
a whole, and optimal function relies on full integrity of the nerv-
ous system. thus, even small deviations from optimal develop-
ment may lead to dysfunction and risk of disease, with negative 
consequences for health, quality of life, academic achievement, 
and economic productivity (Pichery et al., 2011).
In the past, seminal observations were made, but had little im-
mediate consequence, in part because of traditional skepticism 
toward a new paradigm, and because prevention appeared to be 
expensive or impractical. Among major discoveries, two pedia-
tricians in Boston discovered that children with lead poison-
ing did not completely recover, as was thought at the time, but 
showed mental sequelae and school failure at follow-up (Byers 
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3  Clinical perspectives of developmental  
neurotoxicity 
Roberto lucchini and Antonio Persico
During the conference it was acknowledged that the human pop-
ulation displays large genetically-driven inter-individual differ-
ences in sensitivity to potential DNt agents. this variability spurs 
interest into designing a feedback validation process, whereby 
the same in vitro test batteries used to screen chemicals can later 
be also applied to cellular models derived from specific patient 
populations to test for possible individual hyper/hyposensitivity 
to those chemicals. In particular, two paradigms were presented, 
whereby available evidence supports a significant interaction 
between predisposing genetic variants and exposure to develop-
mental neurotoxicants: (a) the cumulative combined exposure to 
pesticides and metals, and the presence of specific genetic vari-
ants shown to interact in determining the risk threshold for neu-
rodegenerative disorders, such as Parkinson’s Disease, Parkin-
sonism and Parkinsonian disturbances in general; (b) a prenatal 
exposure to specific DNT agents in conjunction with a vulnerable 
genetic background, as implicated in the pathogenesis of autistic 
disorder by specific gene-environment interaction models. 
Parkinson’s Disease (PD) is a neurodegenerative disorder 
that typically affects individuals in their old age, after loss of 
dopaminergic neurons in the nigrostriatal portion of the brain. 
the number of these cells declines with age at a rate of 5–10% 
per decade and the characteristic symptoms develop once about 
70% of the dopaminergic neurons in the substantia nigra have 
been destroyed (Nadeau, 1997). the incidence of the disease is 
increasing worldwide, given the increasing life-expectancy and 
duration of individuals’ working lives. Recent estimates predict 
an astonishing increase of neurodegenerative diseases in subse-
quent years not only for elderly people, but also within the mid-
dle aged population (Albert, 2007). therefore this trend may not 
only relate to the increasingly aging population per se, but also 
to a wider and more frequent exposure to neurotoxicants. this 
growing trend is estimated to affect mostly those countries that 
are now rapidly industrializing which have poorly controlled 
exposure conditions, such as China, India, Brazil, and Bangla-
desh (Dorsey et al., 2007). 
An important contribution to these diseases may be inad-
equate control of lifetime exposure to neurotoxicants, starting 
from prenatal life to old age. early life exposure is likely to play 
a key role within the lifetime exposure scenario, given the po-
tential increased susceptibility to further occupational or envi-
ronmental or dietary exposure occurring in adult life. Pesticides 
and heavy metals are being related by human epidemiological 
studies and animal data to PD and, more in general, to Parkin-
sonian disturbances. Differences in epidemiological classifica-
tion distinguish “classical” idiopathic PD from Parkinsonism 
(elbaz et al., 2002), and environmental exposure is considered 
a potential etiological factor of Parkinsonism, especially for in-
dividuals with a genetic predisposition. Polymorphisms in the 
promoter region of the α-synuclein gene confer a higher sus-
ceptibility to idiopathic PD. thus, interactions with exposure to 
neurotoxicants could play a relevant role in human Parkinson-
ism (Vance et al., 2010). 
  An additional concern is that exposures to these chemicals 
during early development can cause brain injury at dose levels 
much lower than those that affect adult brain (Grandjean and 
landrigan, 2006). How low such doses are is only slowly being 
revealed, e.g., allegedly safe exposures to lead have repeatedly 
been lowered, and a truly safe level seems to be below expo-
sures that are common today (Grandjean, 2010). this notion 
therefore puts additional urgency on finding expedient means 
of identifying developmental neurotoxicants and on preventing 
hazardous exposures.
A rational strategy will require a multidisciplinary effort. 
While this conference highlighted the substantial advances 
made in development and validation of screening test meth-
ods, computational chemistry and systems biology should also 
be utilized. We recently used a large database on protein links 
and protein-protein interactions to examine the pesticide DDt 
and its metabolites in regard to their toxicity potentials (Au-
douze and Grandjean, 2011). this in silico approach appeared 
entirely feasible and useful in pointing to the parent p,p’-DDt 
substance as the main culprit. Similarly, Willinghagen and 
colleagues (2011) use computational tools to demonstrate the 
ability of open sources to predict the effects of ten neurotox-
ins. thus, using the whole spectrum of approaches along with 
clinical and epidemiological evidence, when available, should 
allow integration of information for use in at least a tentative 
risk assessment.
 Past regulatory action to protect brain development has 
been, however, impeded by the high level of proof required for 
decision-making. Interpretation of test results and the rules for 
decision-making must take into account the individual and so-
cietal costs from not acting on information on developmental 
neurotoxicant exposures. Science has a responsibility to address 
key issues of importance for protecting developing brains. tra-
ditionally, research has favored skepticism and required exten-
sive replication before acceptance of a hypothesis (Grandjean, 
2008b). Although this may be appropriate in many connections, 
not heeding early warnings on developmental neurotoxicity 
may ultimately result in adverse effects on the brain functions 
in today’s children and the next generation. the strength of evi-
dence to constitute ‘proof’ must therefore be seen in a societal 
perspective, so that the implications of ignoring a developmen-
tal neurotoxicant are taken into account. As a further concern, 
research in toxicology and environmental health has traditional-
ly focused on a small number of chemical substances, while oth-
ers have been ignored (Grandjean et al., 2011). the well-known 
chemicals that have been most extensively researched include 
developmental neurotoxicants, such as arsenic, lead, mercury, 
and polychlorinated biphenyls.
there is limited evidence for the neurotoxicity in humans 
(adults) of over 200 chemicals (Grandjean and landrigan, 2006) 
and 100 or more developmental neurotoxiciants (Crofton et al., 
2011), but there is a complete absence of testing of thousands 
of routinely used commercial chemicals. this lack of data is a 
huge uncertainty in the need to protect human health, especially 
the developing nervous system. 
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nervous system including neocortex, cerebellum, and hind-
brain. the PON1 gene encodes for an enzyme usually de-
fined as “paraoxonase,” which exerts several enzymatic ac-
tivities including the inactivation of some organophosphorus 
compounds, the degradation of lipid peroxides preventing 
atherosclerosis and vascular disease, the breakdown of bac-
terial endotoxins, and the prevention of protein lactonation. 
Autistic individuals display a significant reduction in Reelin 
protein levels, as well as reduced serum PON1 enzymatic ac-
tivity (Gaita et al., 2010). RelN gene polymorphisms yield-
ing lower Reelin gene expression both in vitro and in vivo, 
are significantly associated with autism, as occurs with PON1 
gene variants responsible for lower gene expression and re-
duced organophosphate detoxification. Therefore, individu-
als carrying genetic variants producing lower amounts of 
Reelin and PON1 enzyme, if exposed to developmental neu-
rotoxicants like organophosphorus pesticides during critical 
periods in prenatal neurodevelopment, could be especially 
vulnerable to undergo abnormal neuronal migration yield-
ing altered neural networks and behavioral autism (Persico 
and Bourgeron, 2006). this model has recently received 
experimental and epidemiological support both in humans 
and in mouse models (eskenazi et al., 2010). An alternative 
mechanism to explain this interaction places greater empha-
sis on excessive prenatal and early postnatal oxidative stress, 
partly OP-driven, than on cholinesterase inhibition (Gaita et 
al., 2010).
2. ATP2B2-SLC25A12-prenatal exposure to polychlorinated bi-
phenyls (PCBs): excessive intracellular Ca2+ has been shown 
to play a relevant role in the pathophysiology of autism (Krey 
and Dolmetsch, 2007). the AtP2B2 gene encodes for the 
plasma membrane calcium AtPase 2 (PMCA2), which re-
moves Ca2+ from the cytoplasm into the extracellular space. 
It is especially critical to the function and plasticity of criti-
cal synaptic sites, such as the parallel fiber-to-Purkinje cell 
synapse in the cerebellar cortex and in parvalbumin-positive 
GABAergic interneurons. ATP2B2 gene variants, possibly 
yielding reduced gene expression and slower Ca2+ clearance, 
are associated with autism in males (Carayol et al., 2011). 
excessive intracellular Ca2+ spikes can in turn interfere both 
with neurodevelopment and with energy production, modu-
lating the activity of the mitochondrial aspartate-glutamate 
carrier AGC1. Interestingly, also the SlC25A12 gene, which 
encodes for AGC1, encompasses genetic variants able to in-
fluence disease risk in autism (Palmieri et al., 2010). Genetic 
vulnerability at the ATP2B2 and SLC25A12 loci could be 
exacerbated by prenatal environmental exposure to PCBs, 
important endocrine disruptors also able to promote Ca2+ 
entry from the extracellular space, and Ca2+ release from the 
endoplasmic reticulum (Pessah et al., 2010). 
3. MET-prenatal exposure to polycyclic aromatic hydrocarbons 
(PAHs): the MET protooncogene encodes for the MET re-
ceptor tyrosine kinase, a key modulator of cell proliferation 
and migration, as well as neurite outgrowth and synaptogen-
esis in the development of the CNS, gut and immune system 
(Campbell et al., 2006). ASD brains display profound 50% 
decreases in Met mRNA and protein on average, compared 
Manganese is a neurotoxicant potentially implicated as an 
environmental factor in the pathogenesis of Parkinsonism. the 
prevalence of Parkinsonian disturbances has been found to be 
significantly higher among lifetime residents in the vicinities of 
ferroalloy plants in Italy and is significantly correlated with the 
manganese level in the deposited dust (lucchini et al., 2007). 
Similarly, increased prevalence of PD was observed in relation 
to the concentration of manganese in total suspended particles 
in Canada (Finkelstein and Jerrett, 2007).
Important evidence from developmental models in mice has 
shown that prenatal or perinatal exposure to a range of envi-
ronmental chemicals, including paraquat, maneb, and orga-
nochlorine pesticides, may either directly cause a reduction in 
the number of dopaminergic neurons in the substantia nigra, or 
cause an increased susceptibility to degeneration of these neu-
rons with subsequent environmental insults or with aging alone 
(Cory-Slechta et al., 2005). Based on the importance of early life 
exposure within the lifetime exposure model, DNt testing must 
be able to predict the long term neurodegenerative effects caused 
by substances acting with a cumulative mechanism of toxicity.
Autism Spectrum Disorder (ASD) is a neuropsychiatric dis-
order characterized by deficits in social interaction and com-
munication, as well as by stereotypic behaviors and insistence 
on sameness, with onset in early childhood prior to three years 
of age. Its incidence has dramatically risen during the last two 
decades from 2-5 per 10,000 to approximately 20-60 per 10,000 
children. Broader diagnostic criteria and increased awareness in 
the medical community have contributed to this trend, but a real 
increase in incidence possibly due to gene-environment interac-
tions is also likely (Grether et al., 2009; Hertz-Picciotto et al., 
2006; King and Bearman, 2009).
Microscopic neurodevelopmental abnormalities uncovered in 
ASD brains strongly support a prenatal origin for autism (Bau-
man and Kemper, 2005), although early postnatal exposures 
could also modulate the behavioral phenotype, as may occur with 
p-cresol (Altieri et al., 2011). Genetics is believed to contribute 
strongly to the pathogenesis of ASD, but initial heritability esti-
mates above 90% (Persico and Bourgeron, 2006) have not been 
confirmed by more recent twin studies, which support a larger 
proportion of variance explained by shared environmental fac-
tors as opposed to genetic heritability (55% vs 37% for strict au-
tism, respectively) (Hallmayer et al., 2011). Furthermore, many 
patients reveal no causal mutations or copy number variants. 
this unexpected complexity has spurred interest into poly-
genic models allowing for gene-environment interactions to 
produce large inter-individual phenotypic variability. the valid-
ity of such models is also supported by known prenatal terato-
logical agents, such as rubella or cytomegalovirus infection, and 
drugs like thalidomide, and valproic acid, which yield autism 
only in a subset of presumably vulnerable individuals (landri-
gan, 2010).
Specifically, three gene-environment interaction models have 
been presented: 
1. RELN-PON1-prenatal exposure to organophosphate pesti-
cides or excessive oxidative stress (Persico and Bourgeron, 
2006): the RelN gene encodes for Reelin, a stop signal criti-
cal to neuronal migration in several regions of the central 
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(Richelson, 1973). In addition to tumor-derived lines, multiple 
mouse stem cell-derived clones are available, including meS-
D3 cells. this cell line is the basis for the validated embryonic 
stem cell test where the cells differentiate into beating cardio-
myocytes (eSt; Spielmann et al., 1997; Seiler and Spielmann 
2011). the meS-D3 cells are also utilized for neural differentia-
tion and show promise for use in screening chemicals for DNt 
(Seiler et al., 2007). Mouse neural progenitor cells (mNPCs) can 
be prepared from embryonic or postnatal mouse pup brains of 
different ages. Such progenitors grow as neurospheres, develop 
in vitro, and are especially valuable as a source of genetically 
manipulated primary cells (Gassmann et al., 2010). 
Human cell systems are recommended as the most relevant 
in the context of the 21st century approach in toxicity testing: 
getting a better prediction of human toxicity by using human 
in vitro models (NRC 2007). Numerous human models are 
currently available, ranging from neuroblastoma lines to stem 
cell-derived systems (reviewed in Coecke et al., 2007). Multiple 
human neuroblastoma cell lines like SH-SY5Y or IMR-32 cells 
(e.g., Kohl et al., 1980; Reynolds and Pérez-Polo, 1975) have 
been applied to many different research questions. However, 
they have a disadvantage in that the expression profiles in these 
cells contain many tumor growth genes. For example, the MeIS 
homeobox genes are overexpressed in neuroblastoma cells and 
this gene amplification influences downstream targets involved 
in developmental signaling pathways, chromatin binding, cell 
cycle control, proliferation, and apoptosis (Geerts et al., 2003). 
Moreover, their ability to respond to oxidative stress is impaired 
(Moors et al., 2009). 
lUHMeS (Scholz et al., 2011) and ReNcell Cx (Donato et 
al., 2007; Breier et al., 2008) cells are not tumor-derived, but 
instead are immortalized cells of primary origin (e.g., by c-myc 
overexpression). this also limits their usage in predicting the 
effects of chemicals on neural cell proliferation, but might al-
low the study of some other endpoints. Alternative human in 
vitro systems like progenitor- or stem cell-based methods have 
been studied intensively over the past decade because they are 
primary, of human origin, and expandable although not immor-
talized (reviewed in Breier et al., 2009). Another advantage of 
some primary cell cultures is the simultaneous differentiation 
into the physiological cell types of the brain, namely neurons 
and glia cells (Moors et al., 2007 and 2009). Presence of glia 
is well known to affect toxicity of chemicals towards neurons. 
therefore, a mixed, more organotypic culture is preferred for 
chemical testing. 
A number of specific cell based methods have been subject to 
more in-depth investigations for suitability in toxicity testing. 
these include stem/progenitor cells derived (i) from human um-
bilical cord blood stem cells, (ii) directly from human fetal brain 
tissue, or (iii) from human embryonic stem cells (eSC). the 
earliest work on such systems included (i) a neural stem cell line 
generated from human umbilical cord blood stem cells (HUCB-
NSC line; Buzanska et al., 2005) and (ii) human neural pro-
genitor cells (NPCs) growing as neurospheres (Fritsche et al., 
2005). the difference in time of origin of these cells (embryonic 
vs. fetal) is complementary, covering the embryonic and early 
fetal period of neurodevelopment, respectively. Both methods 
to matched controls; the MET gene promoter contains the 
single nucleotide polymorphism (SNP) rs1858830, whose C 
allele is significantly associated with autism and with lower 
Met transcription both in vitro and in post-mortem brains 
(Campbell et al., 2006, 2007). Prenatal exposure of mice to 
the PAH benzo(a)pyrene blunts postnatal Met gene expres-
sion and yields behavioral deficits in a novelty test (Sheng et 
al., 2010). therefore, prenatal exposure to PAHs may either 
act in conjunction with the C allele at SNP rs1858830 further 
enhancing autism risk, or alternatively may reduce the pro-
tection conferred by the G allele. 
these three examples of gene-environment interaction are based 
on growing genetic, neurobiological, and epidemiological evi-
dence, not merely on theoretical grounds. they are in no way 
exhaustive, as prenatal exposure to many other chemicals could 
favor the development of autism by interfering with the intrac-
ellular pathways best shown to underlie this disease (excessive 
Ca2+ signaling, PI3K/mtOR/eRK, oxidative stress, decreased 
synaptogenesis, epigenetic abnormalities, decreased oxidative 
phosphorylation). these models merely exemplify the need to 
consider the encounter between DNt agents and an individual, 
or even a fetal-maternal unit. In addition they indicate that what-
ever battery of alternative developmental neurotoxicity test will 
eventually be defined, it should also be employed to assess DNT 
risk in selected patient populations and their first-degree rela-
tives, who may have a lower sensitivity threshold for the nega-
tive consequences of environmental toxins as compared to the 
general population. 
4  State of science: in vitro DNT models  
and endpoints
ellen Fritsche
Pharmaceuticals and industrial chemicals are known to ad-
versely impact neurodevelopmental processes critical for nor-
mal brain development, including: neural progenitor cell (NPC) 
proliferation, migration, differentiation into neurons and glia, 
apoptosis, myelination, synaptogenesis, network formation, as 
well as general or neuronal subtype-specific cytotoxicity (seen 
in vivo as necrosis) or gliosis. In vitro systems cannot mimic the 
complexity of in vivo brain development; however, it is now 
possible to investigate effects of compounds on these processes 
which, when disturbed during critical phases of development, 
result in the formation of a suboptimal organ.
In vitro models which mimic one or more of these endpoints 
are numerous and most current models cover three common spe-
cies: mouse, rat, and human (Coecke et al., 2007; Bal-Price et al., 
2010). Rat cells are commonly used as a cell line or as primary 
cultures. One of the most extensively studied is the PC12 cell, a 
rat pheochromocytoma cell line which has been used since 1976 
(Greene and tischler, 1976). Primary cultures of rat cerebellar 
granule cells are widely used in in vitro models. Gene expres-
sion analysis has been postulated to be a useful tool for predict-
ing DNt in such cultures (Hogberg et al., 2009; Hogberg et al., 
2010). From the mouse, several neuroblastoma cell lines are 
available, e.g., N2a cells (Amano et al., 1972) or N1e-115 cells 
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2011; Novellino et al., 2011; Hogberg et al., 2011). 
It is clear that methods and models are now available that 
cover most of the processes important for neurodevelopment. 
these include NPC proliferation via migration, differentiation, 
neurite outgrowth to synaptogenesis, and network formation. 
Such individual tests could possibly form a DNt testing battery 
in the future. Most of the endpoints are currently low-through-
put and a critical need for future research is to scale-up these 
models to medium (e.g., hundreds of chemicals per month) 
or high throughput (e.g., thousands of chemicals per week). 
What we don’t know yet among the multiple cell models and 
the distinct endpoints is which models are the most predic-
tive. More than likely a certain combination of endpoints and 
models will be needed to obtain the information necessary to 
predict in vivo DNt. Computational modeling and generation 
of data from chemical test sets of DNt positive and negative 
compounds across a variety of the most promising models and 
endpoints is needed.
Research on alternative in vitro methods and models for DNt 
testing has at least three major data gaps to fill: (i) systematic 
comparison of tumor/non-tumor cells, (ii) identification of spe-
cies differences and similarities, and (iii) identification of DNT 
relevant pathways which contribute to DNt and/or determine 
cell type and/or species differences. Over all, in vitro testing 
for DNt follows the same path as the rest of the ‘alternatives to 
animal testing’ field is moving: using human, three dimensional, 
cellular systems for testing disturbances of pathways relevant to 
human, cell-specific, physiological cellular functions.
5  Potential of non-mammalian species  
as relevant DNT models
Stephanie Padilla
Studies of the development of “lower”, alternative species have 
revealed that the mechanisms underlying the development 
and function of the nervous system are surprisingly conserved 
across the phylogenic tree. that is, many of the basic molecular 
developmental events are identical in mammals and in the alter-
native species. Within the last 10 years, these alternative spe-
cies (e.g., small fish models such as the zebrafish Danio rerio) 
have gained popularity as vertebrate models for screening for 
developmentally toxic, specifically neurotoxic, chemicals (see 
a recent review by Padilla and MacPhail, 2011). the popularity 
of alternative species is due primarily to three aspects: (1) mo-
lecular biology has revealed the basic concordance of cellular 
events in a wide range of small fish species to that in mamma-
lian species, including humans; (2) the concordance has been 
verified with advances in genetics and pathway analyses (as a 
result, these alternative species are now being used increasingly 
in probing the basic processes of life and disease); and (3) the 
size and speed of development of small fish makes their use 
particularly ideal for high throughput assays. 
Zebrafish represent an attractive complementary species for 
developmental neurotoxicity assessments. Some of the major 
hurdles associated with in vitro screening are minimized when 
testing with an intact organism. Because the zebrafish liver ma-
have been further developed and characterized, especially for 
their DNt testing applicability ((i): Sun et al., 2005; Jurga et al., 
2006; Buzanska et al., 2009; Zychowicz et al., 2011; (ii): Moors 
et al., 2007, 2009; Schreiber et al., 2010; Gassmann et al., 2010; 
tegenge et al., 2010; Fritsche et al., 2011). Human embryonic 
stem cells were recently differentiated in vitro for the purpose 
of DNt testing. Ylä-Outinen et al., (2010) differentiated eSC-
derived NPCs on multi electrode arrays (MeAs) and observed 
impaired electrical activity in the presence of methylmercury. 
Further development and validation of such techniques to allow 
medium throughput testing is desired.
All these different cell models from various species raise the 
question on the predictivity of the individual models for human 
DNt. No comprehensive investigation on this topic has been 
carried out so far; however, this issue among others is currently 
investigated in the German BMBF (German Federal Ministry 
of education and Research) joint project on the development 
of predictive in vitro tests for DNt (Seiler et al., 2007). there 
are indications that sensitivity towards chemicals (endpoint: vi-
ability) can be similar within tumor cells across different spe-
cies, e.g., rat pheochromocytoma (PC12), mouse neuroblastoma 
(N1e-115), and human neuroblastoma (SH-SY5Y) cells (Mun-
dy et al., 2010). In contrast, normal and tumor cells of the same 
species can differ in their sensitivity towards compounds (Radio 
et al., 2010; Harrill et al., 2011a). Nevertheless, tumor-derived 
cells might still be useful for certain applications (Sarkanen 
et al., 2007; Gustafsson et al., 2010; Podrygajlo et al., 2010). 
Species differences of normal, non-tumor cells, however, are 
an understudied field of research. Besides sporadic publications 
(Abbott et al., 1999; Gassmann et al., 2010) there are very few 
data on direct species comparisons with regard to neurodevel-
opmental toxicity pathways. It is necessary to understand spe-
cies differences in the biology of neurodevelopmental signaling 
pathways and resulting toxicity of chemicals.
Which endpoints have been studied in which models so far? 
the most thoroughly investigated endpoints to date are neu-
ral cell proliferation and neurite outgrowth. the US ePA has 
generated a large amount of data from lots of chemicals across 
different cell types and species for these two endpoints (Radio 
et al., 2008; Breier et al., 2008; Mundy et al., 2010; Radio et 
al., 2010; Harrill et al., 2011; Harrill et al., 2011a; Robinette et 
al., 2011). For chemical effects on neural differentiation, migra-
tion, synaptogenesis and functional network activity, less data is 
available. Differentiation of HUCB-NSC, NPC, or rat CGC into 
neurons and/or oligodendrocytes have also been assessed us-
ing more limited numbers of chemicals (Buzanska et al., 2005; 
Hogberg et al., 2009; Fritsche et al., 2005; Moors et al., 2009, 
Schreiber et al., 2010). Not only the ability to differentiate, but 
also to reach the correct position by cell migration can be stud-
ied, preferably in spherical models (Moors et al., 2007; Moors et 
al., 2009; Schreiber et al., 2010; tegenge et al., 2010). Besides 
these basic cell biological endpoints, chemical effects on more 
functional aspects of neuronal cells have been investigated re-
cently in different cell models, mainly synaptogenesis (Mundy 
et al., 2008; Podrygajlo et al., 2010, Scholz et al., 2011, Harrill 
et al., 2011) and network activity (Görtz et al., 2004; Jurga et al., 
2009; Frimat et al., 2010; Ylä-Outinen et al., 2010; Scholz et al., 
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humans;(2) grouping of chemicals based on similar mode of 
action (MOA); (3) supporting decisions for regulatory actions 
currently based primarily on structure activity relationship; (4) 
screening chemicals for further in vivo testing; and (5) replacing 
in vivo testing for regulatory decision-making. the level of vali-
dation required for these purposes will depend on the defined 
use of the alternative approaches. Significantly more validation 
is needed before application of these approaches can be used for 
screening or replacing in vivo DNt testing.
The use of alternative approaches for the first two applica-
tions can be achieved immediately, with proper validation of 
the specific assay system(s) to test hypotheses regarding mode 
of action (MOA) for a particular chemical or defined group of 
chemicals. Clear descriptions of each of the key events (i.e., 
measurable parameters) linking external dose to biological 
perturbation to ultimate toxicological effect of concern are re-
quired to support an MOA (Seed et al., 2005). Data based on 
integration of animal or human in vitro or in vivo data includ-
ing information on toxicity pathways can be used to improve 
understanding of MOAs and focus further testing and risk as-
sessment decisions on the most sensitive endpoints of concern 
(Plunkett et al., (2010). In addition, alternative methods can 
be used to aid in grouping chemicals based on similar mode 
of action which can: (1) support decisions on cumulative risk 
assessment involving exposures to multiple chemicals with the 
same mode of action, and (2) reduce animal testing by sup-
porting use of toxicology data for a representative chemical 
for a group of related chemicals with similar mode of action 
(GAO, 2005; US ePA, 1999, 2010a). In cases where regula-
tory decisions are based solely on structure activity due to the 
lack of any available toxicity data, data from alternative non-
mammalian or in vitro approaches may provide additional data 
to inform regulatory decisions (GAO, 2005; US ePA 2010a). 
However, recognition of the limitations of these data should be 
clearly acknowledged.
the focus for DNt3 has been on the development and use of 
alternative methods for screening chemicals for developmen-
tal neurotoxicity. the science is at an early stage of develop-
ment and significant efforts are needed to validate a battery of 
tests based on guidance from Crofton et al. (2011). Crofton et 
al. (2011) provides general principles and recommendations to 
“facilitate development of alternative methods for screening 
substances for potential developmental neurotoxicity”, and pri-
marily focuses on protocol optimization and standardization so 
that methods can be compared across laboratories. Reliability 
and repeatability under large-scale conditions (standardization 
and economy of scale) is needed, which is very different from 
small scale use of these technologies to address specific research 
questions. In order to accomplish this, the general guidance 
from Crofton et al. (2011) needs to be translated into specific 
recommendations appropriate for each type of assay. 
towards this effort, questions were developed by regulatory 
and industry scientists participating on the last day of the ses-
sion that identify important issues that need to be addressed 
in order to evaluate data from alternative methods for use in 
screening chemicals for further testing (Fig. 1). Important is-
sues to address include definition of an adverse or biologically 
tures early, the embryo is able to metabolize many protoxicants 
into the active metabolite(s) (tao and Peng, 2009; Goldstone et 
al., 2010). Nervous system development is three dimensional 
with non-neuronal cells playing major roles as they do in the 
development of the mammalian nervous system. Moreover, as 
in the mammalian nervous system, both central and peripheral 
nervous system are present and protected by blood/nerve and 
blood brain barriers. For a clear, concise review of the early 
development of the zebrafish nervous system, see Guo (2009). 
Unlike mammalian experimental models of neurodevelop-
ment, it is extremely easy to modify development through use 
of morpholino knockdowns (for a review see Bill et al., 2009) 
and additionally, to create fluorescent “reporter” fish for ease 
of assessment (e.g., Higashijima, 2008; tsang, 2010). One of 
the most important aspects that a small fish model brings to any 
screening effort is the ability to assess the integration of nervous 
system development via behavioral assessments. Because only 
six days of development are required for a zebrafish larva to dis-
play sensory, motor and cognitive functions, in less than a week 
an investigator can determine whether developmental chemical 
exposure altered nervous system development.
Many of these advantages were exploited by investigators 
presenting at the DNt3 meeting. It was shown that behavio-
ral alterations,whether basal or stimulus-controlled locomotor 
activity, habituation, spontaneous movements (i.e., tail coiling) 
or reflex movements (i.e., startle response) in larval zebrafish 
after developmental exposure often were able to distinguish be-
tween neurotoxic and non-neurotoxic chemicals. Work in multi-
ple laboratories indicated that behavioral endpoints in zebrafish 
larvae are advantageous endpoints for predicting developmental 
neurotoxicity because the tests were able to distinguish between 
compounds known to be developmentally neurotoxic and chem-
icals known to be negative for developmental neurotoxicity. 
Morphometric endpoints were also explored with some groups 
presenting medium-throughput morphometric assessments of 
exposure to neurotoxic compounds using whole-mount immu-
nostaining with neuron specific antibodies or in vivo imaging 
of neuronal cells using novel fluorescent dyes. Combination 
of morphometric and behavioral endpoints in developmentally 
treated fish allows the researcher to capitalize on the positive 
aspects of the zebrafish model while still being able to attain a 
low to medium rate of throughput.
In comparison to the alternative animal model work present-
ed at the DNt2 meeting, the researchers at the DNt3 meeting 
tended to present data comparing the developmental toxicity of 
more extensive panels of test chemicals, and also emphasized 
developing higher throughput methods for all endpoints. 
6  Application of alternative approaches  
for regulatory purposes
Abby li
there are several potential applications of alternative approach-
es for regulatory purposes, including: (1) providing mechanistic 
data for a specific chemical to better understand effects observed 
in whole animals, including extrapolation between rodents and 
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it will be necessary to provide concentration-effect or dose-re-
sponse data that are comparable with data that are being devel-
oped for other toxicity endpoints. ensuring that data generated 
today are of the highest quality will lay a stronger foundation for 
reaching the ultimate goal of rapid and streamlined review and 
assessment to ensure the availability of safer and more effective 
products for the consumer, at reduced costs and environmental 
and health impacts. 
7  Conference conclusions and recommendations
the conference achieved its objective of bringing together the 
stakeholders and experts from diverse scientific disciplines and 
representatives from relevant industries to discuss alternative 
tools for assessing the potential of chemicals to cause devel-
opmental neurotoxicity. Since DNT3 was the first of this series 
of meetings to be held in europe, many more european experts 
significant effect for the specific assay, minimum number of 
dose levels tested (e.g., 10) and replicates (e.g., 3), reporting 
of data (e.g., IC50 and standard deviations), standardization of 
dose-response comparisons with cytotoxicity or overt toxic-
ity, detailed and transparent reporting of specific experimental 
conditions, and development of a common training set of posi-
tive and negative controls (e.g., 5 positive and 5 negative con-
trols including chemicals with toxicity in other systems, but 
not developmental neurotoxicity) for different types of assays 
(Fig.1). Currently, comparisons across laboratories and differ-
ent assays are hampered because of the lack of specific criteria. 
these criteria should also be basic inclusion criteria for data-
mining computational efforts to link results from alternative 
methods with animal or human outcomes similar to those initi-
ated by Martin et al. (2011) for developmental outcomes
In vitro and alternative non-mammalian models are promising 
approaches for screening and prioritizing chemicals. In order 
to focus toxicity testing on the most sensitive adverse effects, 
Fig. 1: An Integrated Evaluation Strategy for the development of new testing methods and the use of data in assessment 
and management decisions. 
The	relationship	between	testing,	assessment,	and	management	research	for	chemicals	is	driven	by	problem	formulation	as	defined	
by decision-making needs. In this tiered evaluation strategy the amount of resource utilization is adjusted for each level to provide 
efficient	and	timely	data	to	address	the	needs	of	particular	decisions.	New	methods	need	to	be	developed	at	all	four	levels	of	
data	generation	to	allow	for	the	most	efficient	assessment	of	the	potential	hazards	of	chemicals	to	the	developing	nervous	system	
(adapted from US EPA, 2011).
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cols can be optimized and standardized for cross-laborato-
ry validation. 
13. the majority of conferees agreed that more “hard facts”, in-
dicators, and evidence are needed to make risk assessment 
decisions. However, others expressed concern that the pro-
tection of the public is not necessarily improved by prema-
ture decisions. With proper validation, alternative approach-
es can be used to screen chemicals and accelerate collection 
of evidence on higher priority chemicals. As pathways of 
toxicity specific for DNT are identified, they should be used 
to develop new endpoints and assays. 
14. A plea was made to apply the precautionary principle, which 
would require to introduce preventive actions already before 
final proof is available, but the majority of conferees agreed 
that more "hard facts", indicators, and evidence are needed. 
the modern tools, i.e. alternative approaches discussed at 
the conference, should accelerate the collection of such evi-
dence. 
8  The future of DNT: an integrated  
evaluation strategy for the development  
and use of DNT data
Kevin Crofton and William Mundy
As this report demonstrates, substantial progress has been made 
in the development of alternative test methods for DNt: 1) In 
vitro and alternative species models have been developed based 
on the conserved, key events of neurodevelopment, 2) assay 
protocols have been evaluated for their application in chemi-
cal testing using the guidance provided in Crofton et al. (2011), 
and 3) data is now being generated using a common test set of 
chemicals in order to determine the predictive ability of vari-
ous assays and their possible use in a tiered approach to chemi-
cal screening and prioritization (Radio et al., 2008; Breier al., 
2008; Harrill, 2011; Shafer, 2011). However, as described by 
li (Chapter 6) there is a need to use the data generated in these 
assays for regulatory purposes beyond chemical prioritization. 
Figure 1 illustrates an Integrated evaluation Strategy which 
is a general framework for the generation and use of data at 
multiple levels in making regulatory decisions (US ePA, 2011). 
The overall goal is efficiency: develop only the data needed for 
making regulatory decisions using the least amount of resources 
possible. the amount of resource utilization is adjusted for each 
level to provide efficient and timely data to address the needs of 
particular risk decisions. 
this Integrated evaluation Strategy envisions different levels 
of information needs/generation (illustrated by the four levels 
in Fig. 1), with each level characterized by increasing complex-
ity and cost. The bars to the far right of the figure show how 
resource needs increase with needs for reduced scientific uncer-
tainty in estimates of hazard and risk. the evaluation strategy 
ranges from an initial risk assessment that requires few resourc-
es to evaluate large numbers of chemicals (while tolerating high 
levels of uncertainty) to a more complex, advanced risk assess-
ment that requires substantial resources to evaluate only a few 
chemicals (with lower levels of uncertainty). Although shown 
and stakeholders participated and joined the discussion on DNt 
alternatives, bringing to the table their own data and experience. 
At the conclusion of the conference, general consensus was 
reached on the following:
1. there is an urgent need to develop alternative test systems/
testing strategies that will allow for faster and more cost ef-
ficient testing of chemicals for developmental neurotoxicity. 
Critical to these methods is the need to predict adverse neu-
rodevelopmental outcomes in humans.
2. DNt models with high throughput capacity are needed to 
deal with the very large number of chemicals that have to be 
tested for DNt potential.
3. There has been significant progress since the last DNT2 
meeting in applying in vitro and non-mammalian test sys-
tems to DNt, however, much remains to be done to validate 
reliable alternative test systems for identifying chemicals 
with DN potential.
4. While there is general consensus that a battery of alterna-
tives will be needed, at present there is insufficient data to 
determine which models and/or which endpoints are mini-
mally required to reliably screen for human DNt potential.
5. A critical need is to generate data with each alternative 
method using a large number of test chemicals across a wide 
range of concentrations. Preferably a comparable or similar 
list of test chemicals should be used in each model and in 
each laboratory to facilitate comparison of the results.
6. It is necessary to identify a reference set of chemicals for 
evaluating the reliability and relevance of alternative DNt 
models. this includes both in vitro models and alternative 
species.
7. Cell-based assays mimicking important key aspects of brain 
development (proliferation, migration, differentiation, syn-
aptogenesis, network formation, etc.) should be applied as 
in vitro DNt functional endpoints for use in drug discovery, 
hazard identification, and risk assessment.
7. While available in vitro models cannot mimic the complex 
interactions triggered by an initial chemical challenge to neu-
ronal damage, they may have the capacity to assess whether 
a chemical triggers critical mode(s) of action (MoAs). their 
importance will therefore increase once these critical MoAs 
are identified and suitable tests developed.
8. there is a need for data comparing similar endpoints in 
models from different species (human versus rat versus 
mouse versus zebra fish, etc.). 
9. Computational toxicology and modeling should also be ap-
plied to evaluate the predictive capacity of tests and test bat-
teries.
10. Relevance of the data from in vitro and alternative species 
has to be cautiously evaluated when extrapolating to hu-
mans.
11. Identified pathways of toxicity specific for DNT should be 
used to develop new endpoints and assays. 
12. the future success of applying these approaches for risk 
assessment purposes or data-mining computational efforts 
depends upon the quality and reliability of the data gen-
erated today. Specific criteria based on general principles 
outlined by Crofton et al. (2011) are needed so that proto-
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chemicals suspected of nearing or exceeding the threshold of 
acceptable health or the involvement of highly susceptible ex-
posed populations. Research at level 4 will require a more com-
plete understanding of the key elements of the toxicity pathways 
which underlie the phenotypic, cell-based data obtained using 
the assays described in this meeting, along with the demonstra-
tion of how data fits into adverse outcome pathways leading to 
developmental neurotoxicity. Initially, research at this level will 
cost more, but will result in reduced uncertainty in estimates of 
risk and improving the protection of human health. 
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